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Identity 
Other names: MMP-X1, MT1-MMP, MTMMP1 




MMP14 spans 11009 bp on chromosome 14 in the 
region of q11.2. It consists of 10 exons. 
Transcription 
The human MMP-14 (MT1-MMP) transcript has been 
determined to be 3558 bp in length before splicing a d
1749 bp after splicing. The start codon (ATG) of 
MMP-14 gene exists in the first exon and the stop 
codon (TGA) is present in the last and longest exon of 
the transcribed product of MMP-14. No TATA box, 
which controls the expression of 30% of all genes 
found in the human genome, is found in the proximal 
region in the MMP-14 promoter. In the promoter 
region, Egr-1 has been reported to be one of the most 
important transcription factors regulating the 
expression of MMP-14. MMP-14 expression is also 
regulated by other transcription factors, including AP-
4, NF-kB, c-ETS1 and p53. However, some common 
transcription factors, such as AP-1, AP-2 and TGF-
alpha, which play major roles in the regulation of other 
MMPs do not have binding sites within the promoter of 
MMP-14. Besides these common transcription factors, 
MMP-14 expression is also regulated by hypoxia 
inducible factor 2a (HIF-2alpha) under hypoxic 
conditions. Two HBSs (HIF binding site) have been 
identified in the proximal promoter region, the one 
around -125 bp relative to the transcription start site is 
shown to affect MMP-14 transcription. Some growth 
factors and cytokines, e.g IL1B, EGF, TNFalpha, 
bFGF, GM-CSF, SF/HGF, and TGF-beta have also 
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Schematic representation of the domain structures of MMP-14 (domains are not scaled). 
 
Two functional SNPs in the MMP-14 promoter have 
been found in focal-segmental glomerulosclerosis 
(FSGS) disease. -378 T/C and -364 G/T alterations 
cause a reduction in the expression of MMP-14 and 
correlate with significant risk reduction of FSGS. 
Epigenetic regulation is also involved in the regulation 
of MMP-14 expression. Hypermethylation of the 
CpG100 island, which spans a region from the 
proximal promoter to the 1st intron of MMP-14, and 
trimethylation of Histone H3 lysine-27 (known as a 
repressive marker) are determined as epigenetic 
controls causing the transcriptional silencing of MMP-
14. 
Pseudogene 
No pseudogenes have been identified. 
Protein 
Description 
Matrix metalloproteinases (MMPs) compose one of the 
metzincins super family also known as zinc 
endopeptidases. Highly conserved motif of this family 
contains three histidines that bind zinc ion in the 
catalytic site of the protein and conserved methionine. 
Besides the secreted MMPs of the MMP family, six 
membrane type-MMPs have been identified so far, all 
with similar domain compositions. The best 
characterized MT-MMP is MMP-14 or MT1-MMP, 
which contains seven domains from N-terminus to C-
terminus: a signal peptide leading MMP-14 into the 
secretory pathway; a propeptide domain maintaining 
MMP in a latent form; a catalytic domain responsible 
for enzymatic activity; a hinge region maintaining 
proper conformation; a hemopexin domain required for 
substrate reorganization; a transmembrane domain 
anchoring MMP into the plasma membrane; and a 
cytoplasmic domain required for endocytosis. MT-1, 
MT2-, MT3- and MT5-MMPs all contain seven similar 
domains, whereas MT4- and MT6-MMPs lack the 
transmembrane and cytoplasmic domains. Both MT4- 
and MT6-MMPs are linked to the cell surface through 
GPI-anchorage. There is a furin consensus sequence 
(Arg108-Arg109-Lys110-Arg111) between MMP-14 
propeptide and catalytic domains. Furin has been 
reported to be responsible for MMP-14 activation. 
However, the activation mechanism of MMP-14 is still 
under debate. The hemopexin-like domain of MMP-14  
is the largest domain, and it provides a suitable flat 
surface for the protein-protein interactions with te 
existence of four bladed beta-propeller structures. 
Expression 
MMP-14 is widely expressed in human tissues. Its 
expression has been proven in the adult human 
intestine, kidney, lung, ovary, placenta, prostate, nd 
spleen. Increase in its expression level has also been 
observed in the wound healing area. A Mouse 
embryogenesis study provides evidence for the 
expression of MMP-14 mainly in the muscle cells, 
fibroblast, chondrocytes, and neural cells. MMP-14 is 
upregulated in most human cancers. Both cancer and 
stromal cells have been reported to be upregulated in 
tumor tissues. 
Localisation 
Plasma Membrane (single-pass type I membrane 
protein). MMP-14 contains a 24 amino acid 
hydrophobic motif at the C-terminus which is 
responsible for plasma membrane localization of 
MMP-14. 
Function 
MMP-14 plays an important role in remodelling of 
extracellular matrix (ECM) and enhancing cell 
migration. Besides the role of MMP-14 in these 
pathophysiological processes, it also plays an important 
physiological role during development. Studies 
performed with MMP-14 null mice have shown the 
importance of its function during embryogenesis as the 
lack of MMP-14 caused craniofacial dysmorphism, 
arthritis, osteopenia, dwarfism, fibrosis of soft tissues 
and premature death. In the adult life, MMP-14 is also 
required for the wound healing process. All of these 
functions are related to MMP-14's cleavage or 
activation of the protein within its substrate profile, 
which includes proteins in ECM, pro-MMPs, cell-
adhesion molecules, cytokines, growth factors and 
receptors on the cell membrane. Recent studies have
also demonstrated the activation of signal transduction 
pathways via the cytoplasmic tail of MMP-14 
important for the invasion process. Functions of MMP-
14 can be summarized under the categories of 
activation of proMMMPs; degradation of ECM; 
shedding of cell surface molecules; cleavage of 
cytokines and growth factors; and activation of ERK 
cascade.  
I-) Activation of proMMPs and degradation of ECM 
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Pro-MMP2 was the first identified substrate of MMP-
14 and the trimolecular complex consisting of MMP-14 
and proMMP2-TIMP2 has been investigated very well 
for many years. TIMP2 (tissue inhibitor of 
metalloproteinases-2) is actually the inhibitor of the 
MMPs. However, low concentrations of TIMP-2 aids 
in the activation of proMMP-2 by MMP-14 within this 
complex by binding to the catalytic domain of MMP-14 
and the C-terminal domain of pro-MMP2. Following 
the formation of the triplex, a second MMP-14, which 
is free of TIMP-2, forms a dimer with the pre-existing 
MMP-14 on the cell membrane and cleaves the latent 
pro-MMP2 to produce active MMP2. Active MMP-2 
can then participate in other events such as the 
degradation of collagen type-IV, a major protein 
component of the basement membrane, which is not 
cleaved by MMP-14 itself. Another substrate of MMP-
14 within the MMP family is the pro-MMP-13, which 
also functions as a collagenase in the surrounding tissue 
after its activation. 
Besides activation of MMPs, especially pro-MMP-2, 
MMP-14 cleaves many proteins in the ECM and 
changes the composition of the matrix. Type I-Type II-
Type III collagen, gelatin, fibronectin, laminin-1 and -
5, fibrin and proteoglycans are the major direct targets 
of MMP-14 in the extracellular environment. Out of 
these substrates, collagen makes up a significant 
portion of the ECM and acts as a barrier for migratory 
cells. Within the collagenases, which includes MMP-1, 
MMP-2, MMP-8, MMP-13, only MMP-14 can 
stimulate invasion into collagen by epithelial cells, 
fibroblasts, and cancer cells. MMP-14 concentrates in 
the protrusions of the cells, called lamellipodia in 
normal cells and invadopodia in cancer cells, to induce 
a significant increase in cell migration and invasion by 
degrading components of the ECM and making a path 
in through the surrounding tissue. In this aspect, MMP-
14 should be bound to the plasma membrane in vivo, as 
membrane-bound MMP-14 has been demonstrated to 
be more proteolytically active than the soluble 
recombinant MMP-14. 
II-) Shedding of cell surface molecules 
Studies underlying the mechanism of the constitutive 
shedding of CD44 from the human melanoma cell 
surface implicated the necessity of MMP-14 with the
presence of ADAM-10 for this process. Especially in 
the hyaluronan based matrix, cleavage of CD44 at the 
stem region by MMP-14 sheds these molecules from 
the cell surface and concurrently promotes the 
migration of the cells from the leading edge. Another 
cell adhesion molecule, E-cadherin, is also cleaved by 
MMP-14 to disrupt contact between cells. In the 
ischemia-induced ARF (acute renal failure), MMP-14 
expression is required for the disruption of the 
cadherin/catenin complex. Syndecan-1 is another cell 
surface molecule which is cleaved by MMP-14. 
III-) Cleavage of cytokines and growth factors 
MMP-14 indirectly plays a major role in cleavage of 
the cytokines and growth factors by activating pro-
MMP-2 and pro-MMP13. It also makes direct contact 
with several chemokines and growth factors including; 
the neutrophil chemokine IL-8, secretory leukocyte 
protease inhibitor, pro-tumor necrosis factor, death 
receptor-6, and connective tissue growth factor.  
IV-) Activation of ERK cascade by the cytoplasmic tail
of MMP-14 
In several studies, overexpression of MMP-14 has been 
reported to activate the ERK cascade. It is not yet clear 
how MMP-14 activates ERK signalling, but 
overexpression of the cytoplasmic-deleted form of 
MMP-14 has been shown to eradicate ERK activation. 
Within the cytoplasmic tail, the 573YCQR576 motif 
has been suggested to be involved in ERK activation. 
In addition to ERK activation, the role of MMP-14 in
the p38 and JNK pathway has also been investigated. 
V-) Inhibition of MMP-14 function 
Function of MMP-14 can be abolished either by TIMPs 
(Tissue Inhibitor of MetalloProteinases) or proteolytic 
degradation. TIMP-2, -3 and -4 but not TIMP-1 
specifically inactivates the functions of MMP-14. 
Besides TIMPs, RECK and N-Tes can also block the 
activity of MMP-14 in a similar manner. For the 
proteolytic cleavage of MMP-14, membrane bound 
MMP-14 should be internalized by the clathrin-
dependent and caveolae-dependent pathways. There is 
an AP-2 binding site in the cytoplasmic domain of 
MMP-14, 571LLY 573 which is required for the 
incorporation of MMP-14 into clathrin-coated vesicles. 
The palmitoylation of the C574 right after the AP-2 
binding site has also been demonstrated to be an 
essential modification for the internalization of MMP-
14. 
Homology 
All MT-MMPs have shown a 40-50% identity 
according to their amino acid sequence. In the 
phylogenetic tree, MMP-14 shares the highest 




Degradation of the ECM by MMP-14 has been linked 
to proliferation, invasion and metastasis of cancer cells 
in most cancer types. The expression level of MMP-14 
has also been correlated with invasiveness in many 
cancer cell lines, especially for breast carcinoma. 
Increase in the MMP-14 expression level has also been 
observed in a variety of human tumors, including lung, 
gastric, breast, colon, liver, pancreatic, thyroid, head 
and neck, ovarian, prostate, bladder, cervical and brain 
tumors. Genetic alterations, such as gene amplification 
or activating mutations, have not been observed for 
MMP-14 in these cancer types, therefore up regulation 
of MMP-14 has been linked to the transcriptional 
changes during tumor formation. Immunohistochemical 
and in-situ hybridization analysis have demonstrated 
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the presence of MMP-14 in both tumor cells and 
stromal cells. Interestingly, most of the MMP-14 
expression is produced by the stromal cells rather t an
the cancer cells in many tumor types, including breast 
and lung tumors. The possible explanation for this 
observation is the production of Extracellular Matrix 
Metalloproteinase Inducer (EMMPRIN) by the cancer 
cells on their cell surface. EMMPRIN stimulates the 
surrounding stromal cells to produce MMPs, including 
MMP-14. However, in some human cancers, including 
thyroid, brain, and head and neck cancer, a majority f 
the MMP-14 expression has been shown to be 
produced by the cancer cells rather than surrounding 
stromal cells. Another major role of the MMP-14 
expression for tumor formation is the upregulation of 
VEGF production. VEGF is the key molecule for the 
vascularisation of tumor cells and angiogenesis. For the 
VEGF gene transcription, C-terminal of MMP-14 in the 




In the numerous stages of atherosclerosis, pro-
inflammatory molecules such IL-1a, TNF-a and 
oxidized-LDL trigger the smooth muscle cells (SMC) 
and macrophages to increase their levels of MMP-14. 
Higher expression of MMP-14 activates its downstream 
molecule, pro-MMP-2, and then both MMP-14 and 
MMP-2 contribute to the abnormal matrix turnover, 




It has been reported that fibroblasts, macrophages, and 
osteoclast-like cells in both the lining and sublinig 
layers of the rheumatoid synovial tissue have higher 
expression of MMP-14 and MT3-MMP. Effects of 
MMP-14 have been implicated in the destruction of 
tissue seen in arthritis. Successful suppression of the 
joint destruction has also been observed after treatm nt 
with one of the MMP-14 inhibitors, called FR217840. 
Neurologic disease 
Note 
Neurons and astrocytes have been known to express 
MMPs and remodel the ECM after nerve injury in the 
body. In the case of amyotrophic lateral sclerosis, 
MMP-14 expression has been found to be increased in 




Vascular endothelial cells and bronchial epithelial cel s 
of the lung were injured by the high volume ventilation 
in the ventilator-induced lung (VIL) rat model. In the 
injured cells of the VIL, an increase in the MMP-14  
expression has been reported. Prinomastat, an MMP-14 
inhibitor, treatment of the VIL rat has also been shown 
to abolish the injury. 
Kidney disease 
Note 
Data suggest that the development of crescentic 
glomerulonephritis, a kidney disease characterized by 
inflammation of the glomeruli or small blood vessels, 
triggered by the expression of MMP-14 in 
macrophages. In this disease, MMP-14 activates 
proMMP-2, and then they both contribute to the 
pathological degradation of the ECM. 
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